Exercise Intervention for Multiple Sclerosis: the Sheffield ExIMS trial
| ISRCTN | ISRCTN41541516 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN41541516 |
| Secondary identifying numbers | Version 1: 15/08/08 |
- Submission date
- 16/10/2008
- Registration date
- 05/02/2009
- Last edited
- 05/12/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Plain English Summary
Background and study aims
Multiple sclerosis (MS) is one of the most common diseases of the central nervous system (brain and spinal cord) in young adults. Healthy nerves are coated in a fatty casing (myelin sheath) which helps messages to travel quickly and smoothly along them. When a person is suffering from MS, the immune system, which normally helps to protect against infection, attacks and gradually destroys the myelin sheath (demyelination). This means that messages cannot travel along the nerves effectively causing a range of disabilities. A number of recent studies have shown that exercise is an effective way of improving functioning and mobility in people suffering from MS. The aim of this study is to investigate the effectiveness of a 12-week exercise programme in patients with mild to moderate MS.
Who can participate?
Adults with MS who are able to walk a distance of 10 meters.
What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group take part in a 12 week exercise programme. This involves two supervised and one home-based session per week for six weeks and then one supervised and two home-based sessions per week for six weeks. The sessions take place in small groups and involve short bouts of low to moderate intensity exercise. Those in the second group continue with their normal support alone during the study. At the start of the study and then again after 12 weeks and a further six months, participants in both groups complete a walking test to assess their abilities and complete a number of questionnaires in order to find out if their quality of life and other MS symptoms have improved.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
Centre for Sport and Exercise Science, Sheffield Hallam University (UK)
When is the study starting and how long is it expected to run for?
January 2009 to January 2012
Who is funding the study?
Multiple Sclerosis Society (UK)
Who is the main contact?
Dr John Saxton
j.m.saxton@shu.ac.uk
Contact information
Scientific
Centre for Sport and Exercise Science
Sheffield Hallam University
Collegiate Hall
Collegiate Crescent Campus
Sheffield
S10 2BP
United Kingdom
| Phone | +44 (0)114 225 4414 |
|---|---|
| j.m.saxton@shu.ac.uk |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | The effects of a pragmatic exercise therapy intervention on physical activity and important health outcomes influencing maintenance in people with multiple sclerosis (PWMS) |
| Study acronym | ExIMS |
| Study hypothesis | 1. People with multiple sclerosis (PWMS) who are randomised to pragmatic exercise therapy will have improved functional and health outcomes in comparison to usual care only controls at three-months and six-months of follow-up 2. PWMS who are randomised to pragmatic exercise therapy will have increased structured exercise and free living physical activity levels in comparison to usual care only controls at three-months and six-months of follow-up 3. Inclusion of a pragmatic exercise therapy intervention in the patient care pathway is a more cost-effective treatment strategy than current medical care alone in PWMS |
| Ethics approval(s) | South Yorkshire Research Ethics Committee, 28/10/2008 (ref: 08/H1310/69) |
| Condition | Multiple sclerosis |
| Intervention | Exercise Group: A 12-week intervention period is planned for the exercise group, with a more frequent contact phase during the first 6-week block (two supervised exercise sessions at the centre and one home-based session a week), and reduced contact during the second 6-week block (one supervised session and two home-based sessions a week). Sessions will be conducted in small groups (up to 3 PWMS) and will consist of short bouts (e.g. 5 x 3-min, with 2-minute rest intervals) of low to moderate intensity exercise (50 - 69% maximum heart rate). In accordance with recent recommendations the intervention will be stage-adapted and participants will be encouraged to exercise within their own capabilities. Usual Care: The usual care group will continue with their normal support during this time period. |
| Intervention type | Other |
| Primary outcome measure | 1. Physical activity levels 2. Six-minute walking test All outcome measures will be taken at baseline, 12-weeks and at 6-months follow-up. |
| Secondary outcome measures | 1. Neurological impairment and clinical functional mobility 2. Quality of life 3. Fatigue 4. Focus groups and interviews 5. Immunological analysis All outcome measures will be taken at baseline, 12-weeks and at 6-months follow-up. |
| Overall study start date | 01/01/2009 |
| Overall study end date | 01/01/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 120 |
| Participant inclusion criteria | 1. Clinical diagnosis of MS with an Expanded Disability Status Scale (EDSS) score of between 1.0 - 6.5, and able to walk 10 m distance 2. Aged 18 - 65 years, either sex 3. Participants must have been clinically stable for at least 4 weeks prior to entering the study 4. Participants on disease modifying therapy (interferon and glatiramer acetate) must have been stable on this treatment for at least 3 months prior to entering the study 5. Physically able to participate in some form of exercise three times per week 6. Able to provide written informed consent |
| Participant exclusion criteria | 1. Failure to meet any of the above inclusion criteria 2. Experiencing illness that impairs their ability to be physically active three times per week 3. Not willing to be randomised to either the exercise intervention or usual care control group 4. Living more than 20 miles from the trial centre 5. Already engaged in purposeful structured exercise or brisk walking exercise for equal to or greater than three times per week for equal to or greater than 30 minutes per session and have been so on a consistent basis during the previous six months |
| Recruitment start date | 01/01/2009 |
| Recruitment end date | 01/01/2012 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Collegiate Campus
Sheffield
S10 2BP
United Kingdom
Sponsor information
Hospital/treatment centre
Research and Development Department
Third Floor, Pegasus House
463a Glossop Road
Sheffield
S10 2QD
England
United Kingdom
| Website | http://www.sth-research.group.shef.ac.uk |
|---|---|
"ROR" |
https://ror.org/018hjpz25 |
Funders
Funder type
Charity
Private sector organisation / Associations and societies (private and public)
- Alternative name(s)
- Multiple Sclerosis Society of Great Britain and Northern Ireland, The MS Society, MS Society UK, Multiple Sclerosis Society UK, MS Society
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 01/03/2013 | Yes | No | |
| Results article | results | 15/10/2015 | Yes | No |
Editorial Notes
HF 05/12/17: added pub stage.
05/12/2017: internal review.13/04/2016: Plain English summary added.
19/10/2015: Publication reference added.
